Concord Biotech Limited

What they make

1 input Concord Biotech Limited supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Did you know2024

  Concord Biotech is known as an organ transplant immunosuppressant API manufacturer, but sirolimus (rapamycin) — one of their key fermentation products — has arguably become one of the most medically significant molecules of the 21st century far beyond transplant medicine: (1) Cardiac stent coating: Sirolimus-eluting coronary artery stents (the Cypher stent, approved FDA 2003) became a dominant category of cardiac interventional devices. The same rapamycin molecule that prevents kidney rejection coats the metal stents implanted in coronary arteries to prevent restenosis — connecting Concord Biotech's fermentation production to interventional cardiology supply chains serving ~4 million coronary stent procedures annually. (2) Oncology: Everolimus (a sirolimus derivative) is an approved cancer drug for kidney cell carcinoma, breast cancer (Afinitor/Votubia), and pancreatic neuroendocrine tumors — mTOR inhibition from the same molecular scaffold. (3) Rare diseases: Sirolimus is the only FDA-approved treatment for lymphangioleiomyomatosis (LAM) and is used in tuberous sclerosis complex (TSC). (4) Geroscience/longevity: Rapamycin's mTOR inhibition pathway is the leading intervention in aging biology research — extending lifespan in every model organism tested. A production disruption at Concord Biotech's fermentation facility would simultaneously affect transplant immunosuppression, cardiac stent manufacturing supply chains, oncology drug production, and rare disease treatment.

  Concord Biotech Limited ↗

• Concentration2024

  Global tacrolimus API supply is concentrated among 4-5 manufacturers: Concord Biotech (India, ~20-25% share), Biocon (India), Taiyo Pharmaceutical Industry (Japan), and Chinese manufacturers (Huadong Medicine, Zhejiang Hisun). Approximately 450,000 solid organ transplants occur annually worldwide, and essentially every transplant recipient requires lifelong tacrolimus or sirolimus immunosuppression — missing a dose risks acute rejection and organ loss within days to weeks. Unlike most pharmaceuticals where drug shortage leads to therapeutic alternatives, tacrolimus has few clinically equivalent substitutes for stabilized transplant patients already maintained on the drug. The USFDA has designated tacrolimus a "critical shortage" drug category requiring enhanced supply chain monitoring. Geographic concentration of API supply in India (two major manufacturers) and China creates geopolitical vulnerability: trade disruptions, export restrictions, or natural disasters in Gujarat or coastal China could affect transplant patient immunosuppression continuity across US, EU, and global transplant medicine simultaneously.

  Concord Biotech Limited ↗

• Origin2024

  Concord Biotech Limited (NSE/BSE: CONCORDBIO) was incorporated in 1984 in Ahmedabad, Gujarat — in the heart of what became India's largest pharmaceutical manufacturing corridor. The company was founded with a specific focus on complex fermentation-derived pharmaceutical APIs at a time when most global API manufacturers were moving away from fermentation chemistry (expensive, slow, technically demanding) toward synthetic chemical routes. Concord's strategic bet was that fermentation-derived immunosuppressants — tacrolimus, sirolimus, mycophenolate — would become the backbone of the rapidly growing organ transplant medicine market and that very few companies could master the fermentation processes at commercial scale. The transplant immunosuppressant market proved even larger than expected as kidney, liver, heart, and lung transplantation rates grew globally through the 1990s-2010s. Concord Biotech completed its IPO in August 2023 at a ~₹17,500 crore ($2.1B) valuation — a sign of the company's position as an irreplaceable supplier in the transplant medicine supply chain.

  Concord Biotech Limited ↗